{"id":"methotrexate-immediate","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"10-40","effect":"Mucositis"},{"rate":"20-30","effect":"Nausea and vomiting"},{"rate":"5-15","effect":"Hepatotoxicity"},{"rate":"5-10","effect":"Nephrotoxicity"},{"rate":"5-15","effect":"Neurotoxicity (CNS effects)"},{"rate":"10-20","effect":"Alopecia"},{"rate":"10-30","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL2074969","moleculeType":"Small molecule","molecularWeight":"841.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate is a folate antagonist that binds to dihydrofolate reductase and prevents the conversion of dihydrofolate to tetrahydrofolate, a critical cofactor in one-carbon transfer reactions. This disrupts nucleotide synthesis, leading to inhibition of rapidly dividing cells including cancer cells and activated immune cells. The drug is used both as a cytotoxic chemotherapy agent and as an immunosuppressant at lower doses.","oneSentence":"Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:57.709Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Osteosarcoma"},{"name":"Breast cancer"},{"name":"Rheumatoid arthritis"},{"name":"Psoriasis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT03785574","phase":"NA","title":"Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2018-12-24","conditions":"Hydatidiform Mole, Gestational Trophoblastic Neoplasia","enrollment":30},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT06541249","phase":"PHASE2","title":"MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2024-10-02","conditions":"Polycythemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis (MF)","enrollment":54},{"nctId":"NCT06682169","phase":"PHASE3","title":"Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-20","conditions":"Graft-versus-host Disease","enrollment":182},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT07202819","phase":"NA","title":"Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy","status":"RECRUITING","sponsor":"Assiut University","startDate":"2025-09-01","conditions":"Muscle Invasive Bladder Cancer","enrollment":76},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03793478","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-15","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT06199557","phase":"PHASE1, PHASE2","title":"A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2024-05-23","conditions":"Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult","enrollment":48},{"nctId":"NCT02205762","phase":"PHASE2, PHASE3","title":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"North American Consortium for Histiocytosis","startDate":"2016-11-02","conditions":"Langerhans Cell Histiocytosis","enrollment":1400},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT05557110","phase":"PHASE2","title":"Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL","status":"COMPLETED","sponsor":"Chen Suning","startDate":"2022-09-08","conditions":"B Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT03635957","phase":"PHASE4","title":"Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-09-26","conditions":"Gout","enrollment":14},{"nctId":"NCT03994731","phase":"PHASE4","title":"Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-06-13","conditions":"Gout","enrollment":152},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT01614197","phase":"PHASE1","title":"A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2015-07-03","conditions":"Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma","enrollment":16},{"nctId":"NCT01773395","phase":"PHASE2","title":"GVAX vs. Placebo for MDS/AML After Allo HSCT","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-01-08","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":123},{"nctId":"NCT02043587","phase":"PHASE2","title":"Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2014-01","conditions":"Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma","enrollment":31},{"nctId":"NCT00477412","phase":"PHASE1, PHASE2","title":"Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-03","conditions":"Mantle Cell Lymphoma","enrollment":107},{"nctId":"NCT01471444","phase":"PHASE3","title":"Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-11-02","conditions":"Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection","enrollment":256},{"nctId":"NCT01942174","phase":"PHASE3","title":"VACcination In Methotrexate Treated Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2013-09-27","conditions":"Rheumatoid Arthritis","enrollment":276},{"nctId":"NCT01490723","phase":"PHASE2","title":"Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-01","conditions":"Leukemia, Lymphoma","enrollment":20},{"nctId":"NCT01848457","phase":"PHASE2","title":"Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2013-04","conditions":"Osteosarcoma, Nephrotoxicity, Ototoxicity","enrollment":13},{"nctId":"NCT03490396","phase":"PHASE4","title":"Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients","status":"TERMINATED","sponsor":"Midatech Pharma US Inc.","startDate":"2018-05-15","conditions":"Oral Mucositis","enrollment":28},{"nctId":"NCT04157010","phase":"PHASE4","title":"Tocilizumab REMission in Early RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT01875237","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-27","conditions":"Leukemia, Myeloma, Myeloproliferative Diseases","enrollment":3},{"nctId":"NCT03244462","phase":"PHASE1","title":"Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-08-18","conditions":"Inflammation","enrollment":10},{"nctId":"NCT00928200","phase":"PHASE1","title":"Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2009-04-13","conditions":"Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase","enrollment":1},{"nctId":"NCT02281552","phase":"PHASE3","title":"A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-11-18","conditions":"Rheumatoid Arthritis","enrollment":209},{"nctId":"NCT03360760","phase":"NA","title":"Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-08-01","conditions":"Osteosarcoma of Pelvis","enrollment":100},{"nctId":"NCT00397501","phase":"PHASE1, PHASE2","title":"BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2013-10","conditions":"Brain and Central Nervous System Tumors, Breast Cancer, Cognitive/Functional Effects","enrollment":""},{"nctId":"NCT00028756","phase":"PHASE3","title":"Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2001-10","conditions":"Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder","enrollment":285},{"nctId":"NCT01390402","phase":"PHASE2","title":"Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-01","conditions":"Leukemia, Chronic Myelogenous Leukemia","enrollment":6},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT00844298","phase":"PHASE2","title":"Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-01","conditions":"Leukemia","enrollment":91},{"nctId":"NCT01059773","phase":"PHASE4","title":"A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2009-10","conditions":"Psoriasis","enrollment":490},{"nctId":"NCT02196480","phase":"PHASE4","title":"23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2008-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":27},{"nctId":"NCT01258634","phase":"PHASE1","title":"A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2010-07","conditions":"Osteosarcoma, Lung Metastases","enrollment":2},{"nctId":"NCT00016302","phase":"NA","title":"Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-04","conditions":"T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24},{"nctId":"NCT01633983","phase":"PHASE2","title":"Methotrexate for Central Serous Chorioretinopathy Treatment Trial","status":"UNKNOWN","sponsor":"Edward Averbukh","startDate":"2012-08","conditions":"Central Serous Chorioretinopathy","enrollment":20},{"nctId":"NCT00734773","phase":"EARLY_PHASE1","title":"Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2008-11","conditions":"Brain and Central Nervous System Tumors, Lymphoma, Neurotoxicity","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":399,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["conventional methotrexate treatment"],"phase":"phase_3","status":"active","brandName":"Methotrexate - Immediate","genericName":"Methotrexate - Immediate","companyName":"University Hospital, Montpellier","companyId":"university-hospital-montpellier","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division. Used for Acute lymphoblastic leukemia (ALL), Osteosarcoma, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}